Use of t cell engager proteins in the treatment of cancer
By using T-cell adaptor proteins that specifically bind to CD3 and DLL3 and employing a stepwise dosing regimen, combined with chemotherapy and immunotherapy, the problem of poor treatment outcomes in advanced neuroendocrine tumors has been addressed, resulting in safer and more effective treatment and extended survival.
Patent Information
- Application Number
- CN202610592928.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-17
- Publication Date
- 2026-07-17
AI Technical Summary
Existing treatments for advanced neuroendocrine tumors (such as small cell lung cancer, large cell neuroendocrine carcinoma of the lung, and extrapulmonary neuroendocrine carcinoma) are not very effective, lack effective early detection methods, and existing treatment regimens have significant side effects, making it difficult to prolong patients' survival.
By employing T-cell adaptor proteins that specifically bind to CD3 and DLL3, a stepwise dosing regimen is used to gradually increase the dose to reduce the occurrence of cytokine release syndrome, achieving high-dose treatment. This, combined with chemotherapy and immunotherapy, enhances the therapeutic effect.
It significantly improved the treatment efficacy for DLL3-positive cancers, reduced treatment side effects, prolonged patient survival, and provided a more effective treatment option.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Citation Information
Patent Citations
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
WO1990005144A1
Cytotoxicity-inducing therapeutic agent
WO2019131988A1
DLL3-CD3 bispecific antibodies
WO2019234220A1
DLL3 binding proteins and methods of use
WO2020069028A1
DLL3-targeting multispecific antigen-binding molecules and uses thereof
WO2021200898A1